Background: Pneumonitis, the specific toxicity associated with PD-1/PD-L1 inhibitors, is severe and potentially life-threatening, and its incidence and severity are poorly understood among different tumor types or treatment methods. This meta-analysis was performed to compare the incidence and severity of pneumonitis among different tumor types and treatment regimens. Methods: MEDLINE and Embase were retrieved until September 2021. Meta-analysis of the risk of pneumonitis was calculated using a fixed-effect model. Pooled analysis of the incidence of pneumonitis in different tumor types was performed using a metaprop function. Results: Twenty two randomized controlled trials (RCTs) (n = 10,700) were included for pool analysis, and eighteen RCTs (n = 8,852) were eligible for meta-analysis. For all-grade pneumonitis, the risk of the combination therapy (PD-1/PD-L1 plus CTLA-4 inhibitor) was 3.62 times significantly higher than that of monotherapy, and 4.06 and 1.78 times significantly higher than that of chemotherapy and placebo than monotherapy. The incidence of pneumonitis was not significantly different between PD-1/PD-L1 inhibitor versus ipilimumab or between low doses versus high doses. For high-grade (grade ≥3) pneumonitis, the risk in PD-1/PD-L1 inhibitors alone was 3.62 times significantly higher than chemotherapy. No significant difference was found in the incidence of pneumonitis between combination versus monotherapy, monotherapy versus placebo, combination versus ipilimumab alone, monotherapy versus ipilimumab alone, or low doses versus high doses. Conclusions: Compared with chemotherapy, PD-1/PD-L1 inhibitor monotherapy may cause more treatment-related pneumonitis. Increasing the dose of PD-1/PD-L1 inhibitor does not significantly increase the incidence of pneumonitis. Compared with the monotherapy, combination therapy does not increase the incidence of pneumonitis significantly.

1.
Brahmer
JR
,
Drake
CG
,
Wollner
I
,
Powderly
JD
,
Picus
J
,
Sharfman
WH
,
.
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
.
J Clin Oncol
.
2010
;
28
:
3167
75
.
2.
Hamid
O
,
Robert
C
,
Daud
A
,
Hodi
FS
,
Hwu
WJ
,
Kefford
R
,
.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
.
N Engl J Med
.
2013
;
369
:
134
44
.
3.
Melosky
B
,
Cheema
PK
,
Brade
A
,
McLeod
D
,
Liu
G
,
Price
PW
,
.
Prolonging survival: the role of immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer
.
Oncologist
.
2020
;
25
:
981
92
.
4.
Topalian
SL
,
Hodi
FS
,
Brahmer
JR
,
Gettinger
SN
,
Smith
DC
,
McDermott
DF
,
.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
.
N Engl J Med
.
2012
;
366
:
2443
54
.
5.
Topalian
SL
,
Sznol
M
,
McDermott
DF
,
Kluger
HM
,
Carvajal
RD
,
Sharfman
WH
,
.
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
.
J Clin Oncol
.
2014
;
32
:
1020
30
.
6.
Brahmer
J
,
Reckamp
KL
,
Baas
P
,
Crinò
L
,
Eberhardt
WE
,
Poddubskaya
E
,
.
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
.
N Engl J Med
.
2015
;
373
:
123
35
.
7.
Fehrenbacher
L
,
Spira
A
,
Ballinger
M
,
Kowanetz
M
,
Vansteenkiste
J
,
Mazieres
J
,
.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
.
Lancet
.
2016
;
387
:
1837
46
.
8.
Herbst
RS
,
Garon
EB
,
Kim
DW
,
Cho
BC
,
Gervais
R
,
Perez-Gracia
JL
,
.
Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed Death-Ligand 1-Positive advanced NSCLC
.
J Thorac Oncol
.
2021
;
16
(
10
):
1718
32
.
9.
Larkin
J
,
Minor
D
,
D’Angelo
S
,
Neyns
B
,
Smylie
M
,
Miller
WH
,
.
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-Label phase III trial
.
J Clin Oncol
.
2018
;
36
:
383
90
.
10.
Ma
VT
,
Daignault-Newton
S
,
Waninger
JJ
,
Journey
S
,
Chopra
Z
,
Tezel
A
,
.
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma
.
Pigment Cell Melanoma Res
.
2021
;
34
(
3
):
629
40
.
11.
Ribas
A
,
Puzanov
I
,
Dummer
R
,
Schadendorf
D
,
Hamid
O
,
Robert
C
,
.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
.
Lancet Oncol
.
2015
;
16
:
908
18
.
12.
Robert
C
,
Long
GV
,
Brady
B
,
Dutriaux
C
,
Maio
M
,
Mortier
L
,
.
Nivolumab in previously untreated melanoma without BRAF mutation
.
N Engl J Med
.
2015
;
372
:
320
30
.
13.
Weber
JS
,
Kähler
KC
,
Hauschild
A
.
Management of immune-related adverse events and kinetics of response with ipilimumab
.
J Clin Oncol
.
2012
;
30
:
2691
7
.
14.
Awad
MM
,
Gadgeel
SM
,
Borghaei
H
,
Patnaik
A
,
Yang
JC
,
Powell
SF
,
.
Long-term overall survival from KEYNOTE-021 cohort g: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC
.
J Thorac Oncol
.
2021
;
16
(
1
):
162
8
.
15.
Garon
EB
,
Hellmann
MD
,
Rizvi
NA
,
Carcereny
E
,
Leighl
NB
,
Ahn
MJ
,
.
Five-Year overall survival for patients with advanced Nonsmall-cell lung cancer treated with pembrolizumab: results from the phase i KEYNOTE-001 study
.
J Clin Oncol
.
2019
;
37
:
2518
27
.
16.
Garon
EB
,
Rizvi
NA
,
Hui
R
,
Leighl
N
,
Balmanoukian
AS
,
Eder
JP
,
.
Pembrolizumab for the treatment of non-small-cell lung cancer
.
N Engl J Med
.
2015
;
372
:
2018
28
.
17.
Hui
R
,
Garon
EB
,
Goldman
JW
,
Leighl
NB
,
Hellmann
MD
,
Patnaik
A
,
.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
.
Ann Oncol
.
2017
;
28
:
874
81
.
18.
Langer
CJ
,
Gadgeel
SM
,
Borghaei
H
,
Papadimitrakopoulou
VA
,
Patnaik
A
,
Powell
SF
,
.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
.
Lancet Oncol
.
2016
;
17
:
1497
508
.
19.
Reck
M
,
Rodríguez-Abreu
D
,
Robinson
AG
,
Hui
R
,
Csőszi
T
,
Fülöp
A
,
.
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
.
N Engl J Med
.
2016
;
375
:
1823
33
.
20.
Sul
J
,
Blumenthal
GM
,
Jiang
X
,
He
K
,
Keegan
P
,
Pazdur
R
.
FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed Death-Ligand 1
.
Oncologist
.
2016
;
21
:
643
50
.
21.
Mehra
R
,
Seiwert
TY
,
Gupta
S
,
Weiss
J
,
Gluck
I
,
Eder
JP
,
.
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
.
Br J Cancer
.
2018
;
119
:
153
9
.
22.
Seiwert
TY
,
Burtness
B
,
Mehra
R
,
Weiss
J
,
Berger
R
,
Eder
JP
,
.
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial
.
Lancet Oncol
.
2016
;
17
:
956
65
.
23.
Chen
R
,
Zinzani
PL
,
Fanale
MA
,
Armand
P
,
Johnson
NA
,
Brice
P
,
.
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma
.
J Clin Oncol
.
2017
;
35
:
2125
32
.
24.
Balar
AV
,
Galsky
MD
,
Rosenberg
JE
,
Powles
T
,
Petrylak
DP
,
Bellmunt
J
,
.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
.
Lancet
.
2017
;
389
:
67
76
.
25.
Bellmunt
J
,
de Wit
R
,
Vaughn
DJ
,
Fradet
Y
,
Lee
JL
,
Fong
L
,
.
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
.
N Engl J Med
.
2017
;
376
:
1015
26
.
26.
Kobayashi
K
,
Suzuki
K
,
Hiraide
M
,
Aoyama
T
,
Yokokawa
T
,
Shikibu
S
,
.
Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma
.
Oncology
.
2020
;
98
:
237
42
.
27.
Chao
J
,
Fuchs
CS
,
Shitara
K
,
Tabernero
J
,
Muro
K
,
Van Cutsem
E
,
.
Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials
.
JAMA Oncol
.
2021
;
7
(
6
):
895
902
.
28.
Fuchs
CS
,
Doi
T
,
Jang
RW
,
Muro
K
,
Satoh
T
,
Machado
M
,
.
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial
.
JAMA Oncol
.
2018
;
4
:
e180013
.
29.
Postow
MA
,
Chesney
J
,
Pavlick
AC
,
Robert
C
,
Grossmann
K
,
McDermott
D
,
.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
.
N Engl J Med
.
2015
;
372
:
2006
17
.
30.
Weber
JS
,
D’Angelo
SP
,
Minor
D
,
Hodi
FS
,
Gutzmer
R
,
Neyns
B
,
.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
.
Lancet Oncol
.
2015
;
16
:
375
84
.
31.
Motzer
RJ
,
Escudier
B
,
George
S
,
Hammers
HJ
,
Srinivas
S
,
Tykodi
SS
,
.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
.
Cancer
.
2020
;
126
:
4156
67
.
32.
Motzer
RJ
,
Escudier
B
,
McDermott
DF
,
George
S
,
Hammers
HJ
,
Srinivas
S
,
.
Nivolumab versus everolimus in advanced renal-cell carcinoma
.
N Engl J Med
.
2015
;
373
:
1803
13
.
33.
Ansell
SM
.
Nivolumab in the treatment of hodgkin lymphoma
.
Clin Cancer Res
.
2017
;
23
(
7
):
1623
6
.
34.
Ansell
SM
,
Lesokhin
AM
,
Borrello
I
,
Halwani
A
,
Scott
EC
,
Gutierrez
M
,
.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma
.
N Engl J Med
.
2015
;
372
:
311
9
.
35.
Younes
A
,
Santoro
A
,
Shipp
M
,
Zinzani
PL
,
Timmerman
JM
,
Ansell
S
,
.
Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
.
Lancet Oncol
.
2016
;
17
:
1283
94
.
36.
Galsky
MD
,
Saci
A
,
Szabo
PM
,
Han
GC
,
Grossfeld
G
,
Collette
S
,
.
Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275
.
Clin Cancer Res
.
2020
;
26
:
5120
8
.
37.
Sharma
P
,
Retz
M
,
Siefker-Radtke
A
,
Baron
A
,
Necchi
A
,
Bedke
J
,
.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
.
Lancet Oncol
.
2017
;
18
:
312
22
.
38.
Morse
MA
,
Overman
MJ
,
Hartman
L
,
Khoukaz
T
,
Brutcher
E
,
Lenz
HJ
,
.
Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
.
Oncologist
.
2019
;
24
:
1453
61
.
39.
Overman
MJ
,
McDermott
R
,
Leach
JL
,
Lonardi
S
,
Lenz
HJ
,
Morse
MA
,
.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
.
Lancet Oncol
.
2017
;
18
:
1182
91
.
40.
El-Khoueiry
AB
,
Sangro
B
,
Yau
T
,
Crocenzi
TS
,
Kudo
M
,
Hsu
C
,
.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
.
Lancet
.
2017
;
389
:
2492
502
.
41.
Julien
K
,
Leung
HT
,
Fuertes
C
,
Mori
M
,
Wang
MJ
,
Teo
J
,
.
Nivolumab in advanced hepatocellular carcinoma: safety profile and select Treatment-Related adverse events from the CheckMate 040 study
.
Oncologist
.
2020
;
25
(
10
):
e1532
40
.
42.
Rosenberg
JE
,
Hoffman-Censits
J
,
Powles
T
,
van der Heijden
MS
,
Balar
AV
,
Necchi
A
,
.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
.
Lancet
.
2016
;
387
:
1909
20
.
43.
Rittmeyer
A
,
Barlesi
F
,
Waterkamp
D
,
Park
K
,
Ciardiello
F
,
von Pawel
J
,
.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
.
Lancet
.
2017
;
389
:
255
65
.
44.
von Pawel
J
,
Bordoni
R
,
Satouchi
M
,
Fehrenbacher
L
,
Cobo
M
,
Han
JY
,
.
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study
.
Eur J Cancer
.
2019
;
107
:
124
32
.
45.
Apolo
AB
,
Infante
JR
,
Balmanoukian
A
,
Patel
MR
,
Wang
D
,
Kelly
K
,
.
Avelumab, an anti-programmed Death-Ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study
.
J Clin Oncol
.
2017
;
35
:
2117
24
.
46.
Massard
C
,
Gordon
MS
,
Sharma
S
,
Rafii
S
,
Wainberg
ZA
,
Luke
J
,
.
Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer
.
J Clin Oncol
.
2016
;
34
:
3119
25
.
47.
Rotman
J
,
Mom
CH
,
Jordanova
ES
,
de Gruijl
TD
,
Kenter
GG
,
‘Durvit’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer – safety, toxicity and effect on the primary tumour- and lymph node microenvironment
.
BMC Cancer
.
2018
;
18
:
888
.
48.
Michot
JM
,
Bigenwald
C
,
Champiat
S
,
Collins
M
,
Carbonnel
F
,
Postel-Vinay
S
,
.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
.
Eur J Cancer
.
2016
;
54
:
139
48
.
49.
Som
A
,
Mandaliya
R
,
Alsaadi
D
,
Farshidpour
M
,
Charabaty
A
,
Malhotra
N
,
.
Immune checkpoint inhibitor-induced colitis: a comprehensive review
.
WORLD J Clin Cases
.
2019
;
7
:
405
18
.
50.
Tirumani
SH
,
Ramaiya
NH
,
Keraliya
A
,
Bailey
ND
,
Ott
PA
,
Hodi
FS
,
.
Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab
.
Cancer Immunol Res
.
2015
;
3
:
1185
92
.
51.
Champiat
S
,
Lambotte
O
,
Barreau
E
,
Belkhir
R
,
Berdelou
A
,
Carbonnel
F
,
.
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
.
Ann Oncol
.
2016
;
27
:
559
74
.
52.
Gettinger
SN
,
Horn
L
,
Gandhi
L
,
Spigel
DR
,
Antonia
SJ
,
Rizvi
NA
,
.
Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
.
J Clin Oncol
.
2015
;
33
:
2004
12
.
53.
Nishino
M
,
Giobbie-Hurder
A
,
Hatabu
H
,
Ramaiya
NH
,
Hodi
FS
.
Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis
.
JAMA Oncol
.
2016
;
2
:
1607
16
.
54.
Jadad
AR
,
Moore
RA
,
Carroll
D
,
Jenkinson
C
,
Reynolds
DJ
,
Gavaghan
DJ
,
.
Assessing the quality of reports of randomized clinical trials: is blinding necessary
.
Control Clin Trials
.
1996
;
17
:
1
12
.
55.
Antonia
SJ
,
Villegas
A
,
Daniel
D
,
Vicente
D
,
Murakami
S
,
Hui
R
,
.
Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
.
N Engl J Med
.
2017
;
377
:
1919
29
.
56.
Eggermont
AMM
,
Blank
CU
,
Mandala
M
,
Long
GV
,
Atkinson
V
,
Dalle
S
,
.
Adjuvant pembrolizumab versus placebo in resected stage III Melanoma
.
N Engl J Med
.
2018
;
378
:
1789
801
.
57.
Gandhi
L
,
Rodríguez-Abreu
D
,
Gadgeel
S
,
Esteban
E
,
Felip
E
,
De Angelis
F
,
.
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
.
N Engl J Med
.
2018
;
378
:
2078
92
.
58.
Socinski
MA
,
Jotte
RM
,
Cappuzzo
F
,
Orlandi
F
,
Stroyakovskiy
D
,
Nogami
N
,
.
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
.
N Engl J Med
.
2018
;
378
:
2288
301
.
59.
Hamid
O
,
Puzanov
I
,
Dummer
R
,
Schachter
J
,
Daud
A
,
Schadendorf
D
,
.
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
.
Eur J Cancer
.
2017
;
86
:
37
45
.
60.
Herbst
RS
,
Baas
P
,
Kim
DW
,
Felip
E
,
Pérez-Gracia
JL
,
Han
JY
,
.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
.
Lancet
.
2016
;
387
:
1540
50
.
61.
Carbone
DP
,
Reck
M
,
Paz-Ares
L
,
Creelan
B
,
Horn
L
,
Steins
M
,
.
First-line nivolumab in stage IV or recurrent non-small-cell lung cancer
.
N Engl J Med
.
2017
;
376
:
2415
26
.
62.
Larkin
J
,
Chiarion-Sileni
V
,
Gonzalez
R
,
Grob
JJ
,
Rutkowski
P
,
Lao
CD
,
.
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
.
N Engl J Med
.
2019
;
381
:
1535
46
.
63.
Robert
C
,
Schachter
J
,
Long
GV
,
Arance
A
,
Grob
JJ
,
Mortier
L
,
.
Pembrolizumab versus ipilimumab in advanced melanoma
.
N Engl J Med
.
2015
;
372
:
2521
32
.
64.
Wolchok
JD
,
Chiarion-Sileni
V
,
Gonzalez
R
,
Rutkowski
P
,
Grob
JJ
,
Cowey
CL
,
.
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
.
N Engl J Med
.
2017
;
377
:
1345
56
.
65.
Antonia
SJ
,
López-Martin
JA
,
Bendell
J
,
Ott
PA
,
Taylor
M
,
Eder
JP
,
.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
.
Lancet Oncol
.
2016
;
17
:
883
95
.
66.
Long
GV
,
Atkinson
V
,
Lo
S
,
Sandhu
S
,
Guminski
AD
,
Brown
MP
,
.
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
.
Lancet Oncol
.
2018
;
19
:
672
81
.
67.
Motzer
RJ
,
Rini
BI
,
McDermott
DF
,
Redman
BG
,
Kuzel
TM
,
Harrison
MR
,
.
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial
.
J Clin Oncol
.
2015
;
33
:
1430
7
.
68.
Ferris
RL
,
Blumenschein
G
,
Fayette
J
,
Guigay
J
,
Colevas
AD
,
Licitra
L
,
.
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
.
Oral Oncol
.
2018
;
81
:
45
51
.
69.
Robert
C
,
Ribas
A
,
Wolchok
JD
,
Hodi
FS
,
Hamid
O
,
Kefford
R
,
.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
.
Lancet
.
2014
;
384
:
1109
17
.
70.
Atkins
MB
,
Hodi
FS
,
Thompson
JA
,
McDermott
DF
,
Hwu
WJ
,
Lawrence
DP
,
.
Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 Study
.
Clin Cancer Res
.
2018
;
24
:
1805
15
.
71.
Weber
JS
,
Gibney
G
,
Sullivan
RJ
,
Sosman
JA
,
Slingluff
CL
,
Lawrence
DP
,
.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
.
Lancet Oncol
.
2016
;
17
:
943
55
.
72.
Maio
M
,
Scherpereel
A
,
Calabrò
L
,
Aerts
J
,
Perez
SC
,
Bearz
A
,
.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
.
Lancet Oncol
.
2017
;
18
:
1261
73
.
73.
Bouros
D
,
Hatzakis
K
,
Labrakis
H
,
Zeibecoglou
K
.
Association of malignancy with diseases causing interstitial pulmonary changes
.
Chest
.
2002
;
121
:
1278
89
.
74.
Coussens
LM
,
Werb
Z
.
Inflammation and cancer
.
Nature
.
2002
;
420
:
860
7
.
75.
Tan
TT
,
Coussens
LM
.
Humoral immunity, inflammation and cancer
.
Curr Opin Immunol
.
2007
;
19
:
209
16
.
76.
Toh
CK
,
Wong
EH
,
Lim
WT
,
Leong
SS
,
Fong
KW
,
Wee
J
,
.
The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis
.
Chest
.
2004
;
126
:
1750
6
.
77.
Khunger
M
,
Rakshit
S
,
Pasupuleti
V
,
Hernandez
AV
,
Mazzone
P
,
Stevenson
J
,
.
Incidence of pneumonitis with use of programmed death 1 and programmed Death-Ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials
.
Chest
.
2017
;
152
:
271
81
.
You do not currently have access to this content.